OHSU
Return to Listing

1 result(s) for Ibrutinib

PI Name Protocol # Title
Stephen Spurgeon IRB00009556 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080
 

You may qualify for additional trials within our Phase 1 Program